Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ji Hyun Kwon, and Dong-Wook Kim

Disclosures: There is no conflict of interest in connection with this article.

Contributions: D-WK had primary responsibility for study design, collection and assembly of data, data analysis and interpretation, and manuscript writing; S-EL interpreted and analyzed data, performed statistical analysis and wrote the manuscript. SYC, H-YS, and S-HK performed molecular monitoring, and M-YC contributed to data analysis. JSP, H-JK, S-HK, DYZ, SO, HK, YRD, J-YK, J-AK, D-YK, Y-CM, WSL, MHC, JP, and JHK enrolled patients and collected data, and contributed to interpretation.